8-K: NKGen Biotech Secures $2.5M, Issues Warrants to Asia Advisors

NKGen Biotech has entered into a stock purchase agreement with Asia Advisors Limited, raising $2.5 million through the sale of common stock and issuing significant warrants.

Summary

• NKGen Biotech, Inc. (NKGN) completed a private placement with Asia Advisors Limited on September 18, 2025.
• The company sold 10,000,000 shares of common stock at $0.25 per share, generating $2,500,000.
• In addition, NKGen issued a common stock purchase warrant to Asia Advisors to purchase up to 20,000,000 shares of common stock at an exercise price of $0.25 per share, exercisable for five years.
• Asia Advisors also received an option to purchase an additional 20,000,000 shares at $0.25 per share within 12 months, with pro-rata warrants for an additional 20,000,000 shares.
• A key provision allows for the reset of the purchase price for additional shares and the exercise price of all unexercised warrants to a lower price if a majority of warrants from outstanding unsecured convertible debt are reset below $0.25.
• The transaction also includes the establishment of a business advisory board, with Asia Advisors Limited designating a representative (Jinkyu Hong) as long as they maintain at least 10% common equity ownership.
• The proceeds are intended for working capital and general corporate purposes.
• The offering was made under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, indicating a private placement to an accredited investor.
• Shareholder approval is required for the exercise of warrants exceeding currently authorized and unissued shares.

Sentiment

Score: 3

Explanation: While the company secured needed capital, the terms are highly dilutive and reflect a low valuation, suggesting financial distress or significant challenges. The reset clause for warrants indicates investor protection against further price declines.

Positives

• Secured $2.5 million in immediate capital, with potential for an additional $15 million upon full exercise of warrants and options.
• Strategic partnership with Asia Advisors Limited, including a seat on the new business advisory board, potentially bringing expertise and guidance.
• Proceeds allocated to working capital and general corporate purposes, supporting ongoing operations.

Negatives

• Significant potential dilution from the issuance of 10,000,000 shares and warrants for up to 60,000,000 additional shares.
• The purchase price of $0.25 per share is relatively low, potentially indicating a discount to market or a challenging fundraising environment.
• The reset clause for warrant exercise prices could lead to further dilution if triggered by future issuances at lower prices.
• The company's common stock is listed on the OTC Expert Market, which is typically less liquid and transparent than major exchanges.

Risks

• Dilution Risk: Substantial potential dilution from the issuance of shares and the exercise of warrants, especially if the reset clause is triggered.
• Market Price Volatility: The company's stock trades on the OTC Expert Market, which can be highly volatile and illiquid.
• Shareholder Approval Risk: The ability to fully exercise warrants is contingent on shareholder approval to increase authorized common stock.
• Future Capital Needs: While capital was raised, the company's ongoing need for working capital and general corporate purposes suggests potential future capital raises.
• Regulatory Compliance: Ongoing compliance with SEC reporting requirements and potential delisting risks if not compliant with Principal Trading Market rules.
• Intellectual Property Risk: Potential challenges to the company's Intellectual Property Rights or claims of infringement, as noted in the general representations.
• Litigation Risk: General litigation risk, though no material actions are currently pending or threatened.

Future Outlook

The company intends to use the proceeds for working capital and general corporate purposes. The agreement provides an option for Asia Advisors Limited to purchase additional shares and warrants within 12 months, potentially securing further capital. The establishment of a business advisory board with Asia Advisors' representation suggests a strategic collaboration for future business matters.

Management Comments

• The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general corporate purposes.
• The Advisory Board shall have an opportunity to meet with Company management including Chief Executive Officer Dr. Paul Song at least bi-weekly to provide advice to the Company on general business matters.

Industry Context

This capital raise is typical for biotechnology companies, especially those on less liquid markets like the OTC Expert Market, which often rely on private placements to fund research, development, and operational expenses. The low share price and significant warrant coverage suggest a company in an earlier stage of development or facing financial challenges, where access to traditional public market financing might be limited. The strategic advisory board inclusion could be a way to leverage investor expertise beyond just capital.

Comparison to Industry Standards

• The issuance of warrants covering 200% of purchased shares, plus an option for additional shares with pro-rata warrants, is a highly dilutive structure, often seen in financings for companies with significant capital needs or perceived higher risk, particularly those trading on less liquid markets.
• The $0.25 per share price is low, indicating a substantial discount to historical trading prices or a reflection of the company's current valuation challenges.
• The inclusion of a 'reset clause' for warrant exercise prices is a protective measure for the investor against future dilutive financings at even lower prices, which is a common feature in distressed or high-risk private placements.
• The establishment of an advisory board with investor representation is a common practice in strategic investments, providing the investor with influence and oversight, which can be beneficial for corporate governance but also signals a need for external guidance.

Management Changes

Corporate Governance

Legal Proceedings

• No material action, suit, proceeding or investigation pending or, to the Company's Knowledge, currently threatened in writing against the Company or any Subsidiary or any of their respective directors and officers.

Related Party Transactions

• The transaction itself constitutes a related party transaction with Asia Advisors Limited becoming a significant investor.
• The Letter Agreement specifies that transactions between the Company and AlpineBrook Capital GP I Limited, NKMax Co., Ltd., or Paul Y. Song are not considered a 'Change of Control' for warrant redemption purposes, implying existing relationships.

Stakeholder Impact

• Shareholders: Significant potential for dilution from the issuance of shares and warrants at a low price. The reset clause could exacerbate dilution.
• Employees: Proceeds for working capital may help stabilize operations and secure employment.
• Creditors: Capital raise could improve the company's financial position, potentially reducing credit risk.
• Asia Advisors Limited: Becomes a significant equity holder with potential for substantial returns if the stock price increases, and gains influence through the advisory board.

Next Steps

• Company to use proceeds for working capital and general corporate purposes.
• Asia Advisors Limited has a 12-month option to purchase additional shares and warrants.
• Establishment of a business advisory board, including a representative from Asia Advisors Limited.
• Company needs to obtain shareholder approval to increase authorized common stock to allow for full warrant exercise.
• Company must timely file all reports required by the Exchange Act to enable Rule 144 sales.

Key Dates

Recommendation

The terms of this financing, particularly the low share price of $0.25, the substantial warrant coverage (200% of purchased shares plus an option for more), and the warrant reset clause, indicate a highly dilutive event for existing shareholders. While the capital infusion provides short-term liquidity, the terms suggest a company in a challenging financial position, raising concerns about future equity value. The listing on the OTC Expert Market further highlights liquidity and transparency issues. Investors should consider selling due to the significant dilution and the unfavorable terms of this capital raise, which point to underlying financial weakness.

Keywords

NKGen Biotech, NKGN, Asia Advisors Limited, Stock Purchase Agreement, Warrants, Private Placement, Equity Financing, Capital Raise, Dilution, OTC Expert Market, Biotechnology, Corporate Governance, Advisory Board